Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

R. Stupp, S. Taillibert, AA. Kanner, S. Kesari, DM. Steinberg, SA. Toms, LP. Taylor, F. Lieberman, A. Silvani, KL. Fink, GH. Barnett, JJ. Zhu, JW. Henson, HH. Engelhard, TC. Chen, DD. Tran, J. Sroubek, ND. Tran, AF. Hottinger, J. Landolfi, R....

. 2015 ; 314 (23) : 2535-43.

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000008

IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE: To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea. The trial was terminated based on the results of this planned interim analysis. INTERVENTIONS: Treatment with TTFields was delivered continuously (>18 hours/day) via 4 transducer arrays placed on the shaved scalp and connected to a portable medical device. Temozolomide (150-200 mg/m2/d) was given for 5 days of each 28-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival in the intent-to-treat population (significance threshold of .01) with overall survival in the per-protocol population (n = 280) as a powered secondary end point (significance threshold of .006). This prespecified interim analysis was to be conducted on the first 315 patients after at least 18 months of follow-up. RESULTS: The interim analysis included 210 patients randomized to TTFields plus temozolomide and 105 randomized to temozolomide alone, and was conducted at a median follow-up of 38 months (range, 18-60 months). Median progression-free survival in the intent-to-treat population was 7.1 months (95% CI, 5.9-8.2 months) in the TTFields plus temozolomide group and 4.0 months (95% CI, 3.3-5.2 months) in the temozolomide alone group (hazard ratio [HR], 0.62 [98.7% CI, 0.43-0.89]; P = .001). Median overall survival in the per-protocol population was 20.5 months (95% CI, 16.7-25.0 months) in the TTFields plus temozolomide group (n = 196) and 15.6 months (95% CI, 13.3-19.1 months) in the temozolomide alone group (n = 84) (HR, 0.64 [99.4% CI, 0.42-0.98]; P = .004). CONCLUSIONS AND RELEVANCE: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00916409.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000008
003      
CZ-PrNML
005      
20160126092702.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jama.2015.16669 $2 doi
035    __
$a (PubMed)26670971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stupp, Roger $u University Hospital Zurich and University of Zurich, Zurich, Switzerland2Lausanne University Hospital (CHUV), Lausanne, Switzerland.
245    10
$a Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial / $c R. Stupp, S. Taillibert, AA. Kanner, S. Kesari, DM. Steinberg, SA. Toms, LP. Taylor, F. Lieberman, A. Silvani, KL. Fink, GH. Barnett, JJ. Zhu, JW. Henson, HH. Engelhard, TC. Chen, DD. Tran, J. Sroubek, ND. Tran, AF. Hottinger, J. Landolfi, R. Desai, M. Caroli, Y. Kew, J. Honnorat, A. Idbaih, ED. Kirson, U. Weinberg, Y. Palti, ME. Hegi, Z. Ram,
520    9_
$a IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE: To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea. The trial was terminated based on the results of this planned interim analysis. INTERVENTIONS: Treatment with TTFields was delivered continuously (>18 hours/day) via 4 transducer arrays placed on the shaved scalp and connected to a portable medical device. Temozolomide (150-200 mg/m2/d) was given for 5 days of each 28-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival in the intent-to-treat population (significance threshold of .01) with overall survival in the per-protocol population (n = 280) as a powered secondary end point (significance threshold of .006). This prespecified interim analysis was to be conducted on the first 315 patients after at least 18 months of follow-up. RESULTS: The interim analysis included 210 patients randomized to TTFields plus temozolomide and 105 randomized to temozolomide alone, and was conducted at a median follow-up of 38 months (range, 18-60 months). Median progression-free survival in the intent-to-treat population was 7.1 months (95% CI, 5.9-8.2 months) in the TTFields plus temozolomide group and 4.0 months (95% CI, 3.3-5.2 months) in the temozolomide alone group (hazard ratio [HR], 0.62 [98.7% CI, 0.43-0.89]; P = .001). Median overall survival in the per-protocol population was 20.5 months (95% CI, 16.7-25.0 months) in the TTFields plus temozolomide group (n = 196) and 15.6 months (95% CI, 13.3-19.1 months) in the temozolomide alone group (n = 84) (HR, 0.64 [99.4% CI, 0.42-0.98]; P = .004). CONCLUSIONS AND RELEVANCE: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00916409.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a alkylační protinádorové látky $x terapeutické užití $7 D018906
650    _2
$a nádory mozku $x mortalita $x terapie $7 D001932
650    _2
$a karmustin $x terapeutické užití $7 D002330
650    _2
$a chemoradioterapie $7 D059248
650    _2
$a kombinovaná terapie $x škodlivé účinky $x metody $7 D003131
650    _2
$a dakarbazin $x analogy a deriváty $x terapeutické užití $7 D003606
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a předčasné ukončení klinických zkoušek $7 D057239
650    _2
$a elektrostimulační terapie $x škodlivé účinky $x metody $7 D004599
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glioblastom $x mortalita $x terapie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a udržovací chemoterapie $x metody $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Kanada $7 D002170
651    _2
$a Evropa $7 D005060
651    _2
$a Izrael $7 D007557
651    _2
$a Korejská republika $7 D056910
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Taillibert, Sophie $u Assistance Publique des Hôpitaux de Paris, La Pitié-Salpétrière-University Hospital, Pierre and Marie Curie University, Paris, France.
700    1_
$a Kanner, Andrew A $u Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Kesari, Santosh $u University of California, San Diego.
700    1_
$a Steinberg, David M $u Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Toms, Steven A $u Geisinger Health System, Danville, Pennsylvania.
700    1_
$a Taylor, Lynne P $u Tufts Medical Center, Boston, Massachusetts.
700    1_
$a Lieberman, Frank $u University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
700    1_
$a Silvani, Antonio $u Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
700    1_
$a Fink, Karen L $u Baylor University Medical Center, Dallas, Texas.
700    1_
$a Barnett, Gene H $u Cleveland Clinic Foundation, Cleveland, Ohio.
700    1_
$a Zhu, Jay-Jiguang $u Baylor University Medical Center, Dallas, Texas13University of Texas Health Science Center, Houston.
700    1_
$a Henson, John W $u Swedish Neuroscience Institute, Seattle, Washington.
700    1_
$a Engelhard, Herbert H $u University of Illinois, Chicago.
700    1_
$a Chen, Thomas C $u University of Southern California, Los Angeles.
700    1_
$a Tran, David D $u Washington University Barnes-Jewish Hospital, St Louis, Missouri.
700    1_
$a Sroubek, Jan $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Tran, Nam D $u Moffitt Cancer Center, Tampa, Florida.
700    1_
$a Hottinger, Andreas F $u Lausanne University Hospital (CHUV), Lausanne, Switzerland.
700    1_
$a Landolfi, Joseph $u New Jersey Neuroscience Institute, Edison.
700    1_
$a Desai, Rajiv $u Maine Medical Center, Portland.
700    1_
$a Caroli, Manuela $u Fondazione Ospedale Maggiore Policlinico, Milan, Italy.
700    1_
$a Kew, Yvonne $u Houston Methodist Hospital, Houston, Texas.
700    1_
$a Honnorat, Jerome $u Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France.
700    1_
$a Idbaih, Ahmed $u Assistance Publique des Hôpitaux de Paris, La Pitié-Salpétrière-University Hospital, Pierre and Marie Curie University, Paris, France.
700    1_
$a Kirson, Eilon D $u Novocure, Haifa, Israel.
700    1_
$a Weinberg, Uri $u Novocure, Haifa, Israel.
700    1_
$a Palti, Yoram $u Novocure, Haifa, Israel.
700    1_
$a Hegi, Monika E $u Lausanne University Hospital (CHUV), Lausanne, Switzerland.
700    1_
$a Ram, Zvi $u Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
773    0_
$w MED00002973 $t JAMA $x 1538-3598 $g Roč. 314, č. 23 (2015), s. 2535-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26670971 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160126092825 $b ABA008
999    __
$a ok $b bmc $g 1102289 $s 924214
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 314 $c 23 $d 2535-43 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Archiving options